ClinicalTrials.gg
RecruitingNCT06423430TRANSCENDUpdated Oct 16, 2026

Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND)

An interventional study of Sham-stimulation and Active-stimulation in Treatment Resistant Depression, sponsored by Abbott Medical Devices. Recruiting at 26 sites in United States. Open to participants aged 22 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Abbott Medical Devices (part of Abbott) · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years 2 months later.
Updated Oct 16, 2026Site recruiting status changed1 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
22 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 205 studies in Depressive Disorder, Treatment-Resistant with a site in United States — 43 open to participants now, 65 under way, 6 of them phase 3. Depressive Disorder, Treatment-Resistant · United States.

Planned enrollment
47th of 181
100 · median 38
Started
2024
with 15 others
No phase
72 of 205
21 open now
Primary completion
2027-04
later than 22 of 64 live
Registered
171st of 205
by date

Among the 205 studies in Depressive Disorder, Treatment-Resistant with a site in United States, this one is the 47th largest by planned enrollment of the 181 interventional ones that give a count, is one of 16 that started in 2024, is one of 72 with no phase, reaches primary completion later than 22 of the 64 other live ones, and was the 171st registered.

Depressive Disorder, Treatment-Resistant

449 studies on the registry are indexed under Depressive Disorder, Treatment-Resistant; 147 are open to participants now.

Browse Depressive Disorder, Treatment-Resistant studies →

Open to participants now

43 of the 205 studies in Depressive Disorder, Treatment-Resistant with a site in United States are open now. Recruiting first, the newest first:

37 more — sign in →

All 43 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 115 Depressive Disorder, Treatment-Resistant studies recruiting now, 27 (23%) set no upper age limit and 76 (66%) stop at 75 or younger; 1 takes children under 18; 13 take healthy volunteers.

This study: 22 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 205 studies in Depressive Disorder, Treatment-Resistant with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to evaluate the effectiveness and safety of bilateral stimulation of the subcallosal cingulate white matter (SCCwm) using Deep Brain Stimulation (DBS) as an adjunctive treatment of non-psychotic unipolar Major Depressive Disorder (MDD) in adults.

Read the detailed description

The aim of this prospective, multi-centered, double-blind, randomized, delayed-stimulation/ Sham-stimulation controlled 12-month study is to evaluate the effectiveness and safety of bilateral stimulation of the subcallosal cingulate white matter (SCCwm) using the Infinity™ Deep Brain Stimulation (DBS) system as an adjunctive treatment of non-psychotic unipolar Major Depressive Disorder (MDD) for adults who are experiencing a Major Depressive Episode (MDE) with inadequate response to 4 or more antidepressant treatments.

In a double-blind fashion, half the subjects will receive active DBS therapy, while half will receive sham stimulation. After the 12-month endpoint, all subjects will be unblinded to their treatment group, and subjects in the control arm will receive active DBS therapy.

03

Conditions studied

  • Treatment Resistant Depression

Keywords

  • DBS
  • Major Depressive Disorder
  • Bilateral Stimulation
  • Antidepressant Treatment
  • neurostimulation
  • ABT-CIP-10494
04

Who can participate

Ages eligible
22 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The patient must be diagnosed with non-psychotic unipolar Major Depressive Disorder.
  2. The patient must be in a major depressive episode for ≥12 months or have had at least 3 lifetime depressive episodes.
  3. The patient has tried and failed a minimum of four different types of antidepressant treatments as measured by a tool designed for this purpose.
  4. Depression medication and treatment regimen must be stable for a minimum of 4 weeks before the first baseline visit

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or those who plan to become pregnant during study
  2. Presence of other anatomic or comorbid conditions, or other medical, social, or psychological conditions that could limit participation in the study or interfere with adherence to the study protocol.
  3. Current or lifetime history of psychotic features in any Major Depressive Episode.
  4. Has an intracranial Central Nervous System disease that impairs motor, sensory or cognitive function or that requires intermittent or chronic medication.
  5. Significant acute suicide risk.
  6. Diagnosis of Substance Use Disorder or Alcohol Use Disorder without sustained remission (12 months or longer).
  7. Current and ongoing use of neurostimulation treatment that may interfere with DBS therapy/system.
  8. Treatment with another device or investigational drugs.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Sham comparator
    Sham-stimulation group

    Group will be implanted with DBS system but device is not activated for the first 12 months. After 12 months, this group can receive stimulation.

    Device: Sham-stimulation

  • Active comparator
    Active-stimulation group

    Group will have DBS system activated 2 weeks post-implant.

    Device: Active-stimulation

Interventions

  • DeviceSham-stimulation

    Sham-stimulation

  • DeviceActive-stimulation

    Active DBS

06

What researchers measure

Primary outcomes

  1. Change in MADRS total score

    The MADRS absolute change is measured as score change from baseline to the endpoint evaluation period. The Montgomery Asberg Depression Rating Scale (MADRS) consists of 10 items, and each item is rated on a 7-point Likert scale. The sum of the item scores produces a MADRS total score that ranges from 0 to 60, with higher scores reflecting greater depression severity.

    Time frame: 12 months

  2. CGI-I response rate

    The CGI-I response is defined as a rating of "very much improved" or "much improved." The Clinical Global Impression of Severity and Improvement (CGI-I) is a clinician-rated tool used to measure the global impression of a treatment response in a patient's by comparing their baseline condition (i.e., before DBS system implant) with their current state.

    Time frame: 12 months

Secondary outcomes

  1. Percent time in MADRS response

    The Montgomery Asberg Depression Rating Scale (MADRS) consists of 10 items, and each item is rated on a 7-point Likert scale. The sum of the item scores produces a MADRS total score that ranges from 0 to 60, with higher scores reflecting greater depression severity.

    Time frame: 12 Months

  2. Percent time in MADRS partial response

    The Montgomery Asberg Depression Rating Scale (MADRS) consists of 10 items, and each item is rated on a 7-point Likert scale. The sum of the item scores produces a MADRS total score that ranges from 0 to 60, with higher scores reflecting greater depression severity.

    Time frame: 12 Months

  3. Percent time in CGI-I partial response

    The Clinical Global Impression of Severity and Improvement (CGI-I) is a clinician-rated tool used to measure the global impression of a treatment response in a patient's by comparing their baseline condition (i.e., before DBS system implant) with their current state.

    Time frame: 12 Months

  4. MADRS Response Rate

    The Montgomery Asberg Depression Rating Scale (MADRS) consists of 10 items, and each item is rated on a 7-point Likert scale. The sum of the item scores produces a MADRS total score that ranges from 0 to 60, with higher scores reflecting greater depression severity.

    Time frame: 12 Months

  5. Q-LES-Q score change

    The Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) is a self-report measure that assess the degree of enjoyment and satisfaction experienced by patients in various areas of daily functioning.

    Time frame: 12 Months

07

Study locations

25 of 26 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Apr 2027, 31 months after the start.

Of 140 interventional studies with no phase under Depressive Disorder, Treatment-Resistant, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 88. This study's planned 31 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2024
First posted
May 21, 2024
StartActual
Sep 11, 2024
Primary completionEst.
Apr 2027
CompletionEst.
Apr 2029
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added. 2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • USC University Hospital · Los Angeles, United StatesNot yet recruiting→Recruiting
  • University of Minnesota Medical Center Fairview · Minneapolis, United StatesNot yet recruiting→Recruiting
Show site
  • University of Chicago · Chicago, United States
Oct 16, 2026
Site contacts
Changed at 3 sites. See the sites
Show 3 sites
  • USC University Hospital · Los Angeles, United StatesContact •••6000→•••9310
  • The Ohio State University · Columbus, United StatesContact a•••@osumc.edu · •••5517→g•••@osumc.edu
  • University of Texas Austin Dell Medical School · Austin, United StatesContact •••3680→•••3596Contact added a•••@austin.utexas.edu · •••1791
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    1 site added. 2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • USC University Hospital · Los Angeles, United StatesNot yet recruiting→Recruiting
    • University of Minnesota Medical Center Fairview · Minneapolis, United StatesNot yet recruiting→Recruiting
    Show site
    • University of Chicago · Chicago, United States
    Site contacts Changed at 3 sites. See the sites
    Show 3 sites
    • USC University Hospital · Los Angeles, United StatesContact •••6000→•••9310
    • The Ohio State University · Columbus, United StatesContact a•••@osumc.edu · •••5517→g•••@osumc.edu
    • University of Texas Austin Dell Medical School · Austin, United StatesContact •••3680→•••3596Contact added a•••@austin.utexas.edu · •••1791
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06423430
Responsible party
Sponsor
First posted
May 21, 2024
Start date
Sep 11, 2024
Primary completion
Apr 2027 (estimated)
Completion
Apr 2029 (estimated)
Last update
Oct 16, 2026

Study contacts

Natalie Danovsky
Contact
natalie.richardson@abbott.com
+16517563842
Lyndahl Himes
Contact
lyndahl.himes@abbott.com
Brian Kopell, MD
principal investigator · MOUNT SINAI HOSPITAL
Mark George, MD
principal investigator · Medical University of South Carolina

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion